Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal
The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.
Related coverage
- Administrative Declaration of a Disaster for the State of Colorado
- Television Broadcasting Services Des Moines, Iowa
- Request for Extension of an Information Collection-Local Food Directories and Survey
- Regulations Regarding Payment of Tax by Commercially Acceptable Means
- Approval and Promulgation of Implementation Plans; Arizona; Revisions to the Cleaner Burning Gasoline, Winter Oxygenated Fuel, and Gasoline Set-Aside Programs
- Air Quality Plan; Arizona; Pinal County Air Quality Control District; West Pinal County PM10 Nonattainment Area; Fugitive Dust Rules